Skip to search formSkip to main contentSkip to account menu

YM-222714

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

darexaban glucuronide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P‐glycoprotein
We investigated the effects of ketoconazole on the pharmacokinetics (PK) of the direct clotting factor Xa inhibitor darexaban… 
2013
2013
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P‐glycoprotein and CYP3A4
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 
2013
2013
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects
Background. Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial… 
2013
2013
Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects.
BACKGROUND Darexaban is a potent direct factor Xa (FXa) inhibitor developed for prophylaxis of venous and arterial thromboembolic… 
2012
2012
Identification of enzymes responsible for the N-oxidation of darexaban glucuronide, the pharmacologically active metabolite of darexaban, and the glucuronidation of darexaban N-oxides in human liver…
Darexaban maleate is a novel oral direct factor Xa inhibitor. Darexaban glucuronide (YM-222714) was the major component in plasma… 
2011
2011
Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
2011
2011
Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.
Inhibitors of factor Xa (FXa), a crucial serine protease in the coagulation cascade, have attracted a great deal of attention as… 
2010
2010
Co-Administration of YM150, An Oral Direct Factor Xa Inhibitor, and Naproxen Does Not Result In Clinically Relevant Changes to the Pharmacodynamic or Pharmacokinetic Profile of Either Agent
Abstract 4393 Background: YM150, a potent oral direct factor Xa (FXa) inhibitor, is in development for the prevention of venous… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)